Compare CVS Health Corp (CVS) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs KraneShares Electric Vehicles and Future Mobility — how do they compare? CVS Health Corp trades at $104.75 (market cap $135.48B), while KraneShares Electric Vehicles and Future Mobility trades at $30.57. The key difference: CVS Health Corp pays a 2.51% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and CVS Health Corp is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| CVS | KARS | |
|---|---|---|
Market Cap | $135.48B | — |
Sector | Health | Sector/Thematic |
52-Week High | $106.18 | $38.01 |
52-Week Low | $58.75 | $23.10 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
KARS trades at $29.72, down 2.8% in the last 24 hours, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock lacks key financial ratio data, but recent news highlights global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support. However, competition from Chinese automakers and potential US regulatory barriers present challenges.
The outlook for KARS is mixed, with positive industry tailwinds from rising EV adoption offset by technical weakness and competitive risks. Investment opportunities lie in exposure to the expanding EV market, but investors face volatility from geopolitical factors and shifting consumer demand. Caution is warranted given the bearish technical signals and lack of fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
